Endpoints News

6 days ago | endpts.com | Kyle LaHucik

A South Korean biotech working on multi-specific autoimmune disease treatments is looking to make a leap into the US. Curogen, based in Seoul and backed … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

6 days ago | endpts.com | Ayisha Sharma

In the biggest biopharma deal since January, Sanofi is bolstering its rare immunology offering by acquiring Blueprint Medicines for $9.1 billion. The French drugmaker has … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

6 days ago | endpts.com | Andrew Dunn

The small biotech Kymera Therapeutics believes it could have a potential oral competitor to the megablockbuster Dupixent. There’s a long road ahead for Kymera’s immunology … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

6 days ago | endpts.com | Kyle LaHucik

BioNTech bought out its China-based biotech partner Biotheus for $800 million upfront in November. Now, the German drugmaker is set to receive … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

6 days ago | endpts.com | Elizabeth Cairns

Vera Therapeutics’ rare kidney disease candidate atacicept appears to have pulled off an unusual trick: being more effective in Phase 3 than it was in … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.